Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Medicine for treating parkinson's disease and Parkinson's syndrome and its prepn

A Parkinson's disease, Parkinson's technology, applied in the field of traditional Chinese medicine, can solve problems such as on-off phenomenon, end-of-dose phenomenon, and ineffectiveness

Inactive Publication Date: 2006-03-01
GUANGDONG ZHONGSHENG PHARMA
View PDF0 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Generally, the curative effect of dopamine preparations tends to disappear after 5 to 10 years of medication, and the body no longer effectively absorbs and utilizes dopamine, and finally there is no cure.
In addition, most of the drugs for the treatment of Parkinson's disease have more side effects. Most patients with long-term use have hallucinations, dyskinesias, hypotension, stomach discomfort, severe heart failure, arrhythmia, psychosis, movement disorders and other adverse reactions. There may also be special problems such as "on-off phenomenon", "end-of-dose phenomenon" and "dose peak hyperactivity" in the application. At the same time, many comorbidities such as coronary heart disease, hypotension, diabetes, glaucoma, stomach disease, etc. limit the application of western medicine due to adverse reactions.
In addition, dopamine replacement therapy is often less effective or even ineffective for Parkinson's syndrome. Therefore, it is necessary to actively look for other safe and effective treatments to improve the quality of life of patients, especially for early mild patients, which can replace dopamine preparations. Drugs without adverse reactions and drugs that improve the curative effect of dopamine preparations, increase the duration of their curative effect, reduce their adverse reactions, and improve the quality of life of patients with severe patients are the focus of modern Parkinson's disease drug research and development

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating parkinson's disease and Parkinson's syndrome and its prepn
  • Medicine for treating parkinson's disease and Parkinson's syndrome and its prepn
  • Medicine for treating parkinson's disease and Parkinson's syndrome and its prepn

Examples

Experimental program
Comparison scheme
Effect test

experiment example I

[0037] [Experimental example 1] the pharmacological action of medicine of the present invention to unilateral nigrostriatal pathway damage rat model

[0038] This experimental example investigates the motor function of the drug of the present invention on the Parkinson's disease-like model rat caused by unilateral nigrostriatal pathway damage, the level of lipid peroxide in the rat cortex, the content of dopamine in the striatum, and the number of neurons in the substantia nigra. Impact.

[0039] Experimental Materials:

[0040] 1. Animal: SD rat, male, weighing 200±20g

[0041] 2. Reagents and instruments

[0042] Reagents: 6-hydroxydopamine (6-hydroxydapamine, 6-OHDA), octane sulfonate sodium salt (octylsulfate sodium salt, OSA), dopamine (Dopamine, DA), dihydroxyphenylacetic acid (dihydroxyphenylacetic acid, DOPAC), dihydroxy Benzylamine (3,4-dihydroxybenzylamine, DHBA), homovanillic acid (homovanillic acid, HVA), thiobarbituric acid (TBA), ethylenediaminetetraacetic aci...

experiment example 2

[0119] [Experimental example 2] the pharmacological effect of drug granules of the present invention on drug-induced muscle tremor model mice

[0120] In this experiment example, two drug-induced muscle tremor models were selected: arecoline tremor and oxygenated tremorine tremor. Record the latency period and duration of tremor in animals to observe the effect of the drug particles of the present invention on the tremor behavior of the drug.

[0121] Experimental Materials

[0122] 1. Animal: ICR mouse, male, clean grade, body weight 18±2g.

[0123] 2. Reagents: Oxotremorin, Arecoline.

[0124] experimental method:

[0125] 1. Animal grouping and drug administration

[0126] The mice were randomly divided into groups, and the mice in the normal control group were given distilled water for continuous intragastric administration (0.3ml / only) for 3 weeks before giving a single intraperitoneal injection of 0.9% normal saline (0.3ml / only); the mice in the model group were give...

experiment example 3

[0153] [Experimental Example 3] Pharmacological effects of drug granules of the present invention on MPTP-induced PD-like model mice

[0154] Experimental Materials:

[0155] 1. Animals: C57BL mice, half female and half male, clean grade, weighing 18±2g.

[0156] 2. Reagents and instruments: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP).

[0157] Instrument: CS-2 Mouse Autonomic Activity Programmer.

[0158] experimental method:

[0159] 1. Establishment of MPTP-induced Parkinson's disease mouse model: MPTP was directly dissolved in 0.9% sterile saline, and its final concentration was adjusted to 2 mg / ml. Animals in the model group were injected with MPTP20mg / kg continuously intraperitoneally for a total of 8 days.

[0160] 2. Grouping and administration: C57BL mice were randomly divided into groups. Normal control group: After intragastric administration of distilled water for 3 weeks, the same dose of normal saline as ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The medicine for treating Parkinson's disease and Parkinson's syndrome is prepared with ten kinds of Chinese medicinal materials including white peony root, hooked uncaria, gastrodia tuber, puncture vine, abalone shell, etc. It is prepared through the process including the following steps: A. refluxing hooked uncaria, gastrodia tuber, prepared fleeceflower root and red sage with alcohol solution of 10-90 % concentration for several times, merging the extracted liquid and filtering; B. concentrating the filtrate to relative density of 1.0-1.3 while recovering alcohol; C. twice decocting the other medicine materials together with the refluxed dregs, filtering, merging filtrate and alcohol extracted liquid, and concentration to relative density of 1.1-1.4; and D. adding proper amount of supplementary material to prepare medicine preparation. The present invention has unique process and obvious curative effect.

Description

technical field [0001] The invention relates to a medicine for treating Parkinson's disease and Parkinson's syndrome and a preparation method thereof, belonging to the field of traditional Chinese medicines. Background technique [0002] Parkinson's disease and Parkinson's syndrome (Parkinson, PD) are clinical common diseases, especially along with population aging, the proportion and absolute number of elderly population increase gradually, as the Parkinson's disease and Parkinson's syndrome of senile degenerative encephalopathy Its incidence and prevalence are rapidly increasing. Parkinson's disease (PD) is a degenerative disease of the central nervous system with progressive motor dysfunction as the main clinical manifestation. Tremor, stiffness and decreased movement are the most important clinical manifestations. [0003] At present, there is no Chinese patent medicine for the treatment of Parkinson's disease and Parkinson's syndrome on the market. The treatment of Pa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/8988A61K35/56A61P25/16A61K35/618
Inventor 王永炎袁锐光龙超峰谢称石陈木洲
Owner GUANGDONG ZHONGSHENG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com